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Abstract 1 
Staphylococcus aureus is one of the most significant human pathogens that is frequently isolated in 2 
a wide range of superficial and systemic infections. The ability of S. aureus to invade and survive 3 
within host cells such as keratinocytes and host immune cells has been increasingly recognised as a 4 
potential factor in persistent infections and treatment failures. The incorporation of antibiotics into 5 
hyaluronan-cholesterol nanohydrogels (NHs) represents a novel paradigm in the delivery of 6 
therapeutic agents against intracellular bacteria. The work presented herein shows that NHs quickly 7 
enter human keratinocytes and accumulate into lysosomes. When used for targeting intracellular S. 8 
aureus the antimicrobial activity of loaded levofloxacin (LVF) is enhanced, possibly changing the 9 
antibiotic intracellular fate from cytosol to lysosome. Indeed, gentamicin (GM), an antibiotic that 10 
predominantly accumulates in lysosomes, showed significant and equal antibacterial activity when 11 
entrapped into NHs. These results strongly suggest that lysosomal formulations may display 12 
preferential activity towards intracellular S. aureus, opening new avenues for the use of HA-based 13 
NHs for treatment of such skin infections.  14 
 15 
1. Introduction 16 
The opportunistic pathogen S. aureus is a prevalent commensal organism and a significant 17 
mammalian pathogen, frequently associated with a wide range of clinical infections that include 18 
skin, soft tissues and device related infections and bacteraemia[1]. Whilst S. aureus is not 19 
traditionally considered as an intracellular pathogen, there is increasing evidence which suggests 20 
that this microorganism can not only invade and persist in a range of cell types[2], but also that this 21 
adaptation may offer protection from the immune response and be a factor in treatment failure due 22 
to the inability of the antibiotic/antimicrobial agent to target intracellular microorganisms. This 23 
advantageous facet of intracellular adaption is evident in intracellular pathogens such as 24 
Mycobacteriae  which can survive and replicate within macrophages by resisting lysosomal delivery 25 
by residing in early phase endosomal compartments[3], whilst organisms such as Salmonellae and 26 
Brucellae survive by preventing vacuole-lysosome fusion[4] and pathogens such as Shigella spp. 27 
Listeria spp and Rickettsiae are able to escape from phagosomes and survive into the cytosol[5]. To 28 
survive and disseminate intracellularly S. aureus has developed some specific adaptations; one is to 29 
resist the fusion of phagosomes with lysosomes and to multiply within the phagolysosomes of 30 
macrophages[6], whilst others, for example thought such as FnBP-dependent and -independent 31 
pathways have been shown to facilitate S. aureus internalization and survival within human 32 
keratinocytes[2b, 7]. Once internalized, it has been proposed that this offers protection from humoral 33 
immune responses and from the action of several antibiotics[8]. 34 
When treating an intracellular infection, a suitable antibiotic should be chosen in order to ensure 35 
drug concentration above the minimum inhibitory concentration (MIC) and in the same intracellular 36 
location as the target microorganism. Depending on their physico-chemical properties, antibiotics 37 
accumulate in various cell compartments at different concentrations; typically, weak bases tend to 38 
accumulate in membrane-bound acidic compartments, whereas weak acids are excluded from 39 
those sites[9]. Specifically, aminoglycosides[10] and macrolides[11] predominantly accumulate in 40 
lysosomes, whereas quinolones[8a, 12] accumulate in the cytosol. The β-lactams group of 41 
antibiotics[8b] have been shown to accumulate at low level within the cells (predominantly in the 42 
cytosol) likely due to their acidic character. Despite the ability of antibiotics to cross cell membrane, 43 
their intracellular efficacy can be poor due to: I) low intracellular concentrations below the minimum 44 
inhibitory value; II) intracellular environment (e.g. acidic pH) that may affect the antibiotic activity; 45 
III) antibiotic accumulation in subcellular compartments that are different from those in which 46 
pathogens persist. These limitations could potentially be overcome by utilizing suitable nano-47 
carriers which can enhance the intracellular uptake of antibiotics[13] and facilitate the subcellular 48 
targeting[14]. Such nano-carriers can be customized in order to target lysosomes or to escape the 49 
endosome, being released into the cytosol. Indeed, carriers made of polycations can provide a 50 
‘proton sponge effect’[15] or such carriers can be conjugated to membrane-degrading/destabilizing 51 
peptides in order to break down the endosome membrane, allowing the ‘cargo’ release into the 52 
cytosol[16]. In this respect, a number of strategies have been studied for achieving drug delivery 53 
systems that can target specific cellular compartments[14a, 17]. Hyaluronan (HA), a generally non-toxic 54 
and non-sulphated glycosaminoglycan, is a natural component of human skin and is predominantly 55 
employed in the cosmetics industry as a dermal filler [18] or skincare agent or in 56 
viscosupplementation[18b]. A major receptor for HA is CD44, a cell-surface glycoprotein highly 57 
expressed on the surface of keratinocytes[19] and activated macrophages[20]. After binding to CD44, 58 
HA is taken up by cells and delivered to the lysosomes[21]. CD44 appears to be important in the 59 
invasion, survival and persistence of a range of microorganisms within host cells[22]. For example, 60 
Group A Streptococcus (GAS) has been shown to attach to epithelial cells through its HA-rich 61 
polysaccharide capsule which is reported to mediate attachment to CD44 on pharyngeal and 62 
epidermal keratinocytes[23]. Moreover, CD44 was identified as a widely distributed receptor in the 63 
epithelial tissues where colonization and infection occur and represented the major cellular 64 
receptor for the GAS entry into primary mouse keratinocytes[22b]. CD44 has also been implicated in 65 
the cellular internalization of other pathogens such as Mycobacterium tuberculosis in 66 
macrophages[22a] and for Shigella spp in epithelial cells[22d]. Consequently, the application of HA-67 
based nano-carriers may be particularly suitable for targeting intracellular pathogens as: I) a number 68 
of host cells (e.g. keratinocytes and macrophages) highly express CD44 and easily internalize HA;  II) 69 
HA can enter cells through the receptor (CD44) that is also employed by such pathogens; III) like 70 
other nanoparticles, HA nano-carriers can be engineered  in order to target lysosomes or other 71 
cellular compartments[24]; IV) in the cellular micro-environment the HA nano-carriers may be 72 
cleaved by hyaluronidases (HAase) that are produced by several bacteria such as Staphylococcus spp. 73 
and Streptococcus spp.[25], facilitating the release of the drug in situ. Moreover, the scission of HA 74 
can also occur in the presence of host enzymes, acidic pH and free radicals[26], assuring the drug 75 
release within the cells, thus guaranteeing the efficacy of the targeted therapy also against 76 
microorganisms that typically do not produce HAase such as P. aeruginosa[27] and M. Tuberculosis[28]. 77 
The data presented herein show the novel application of self-assembling HA-based NHs[29] for 78 
enhancing the intracellular uptake of antibiotics into human keratinocytes and targeting to 79 
intracellular S. aureus. The efficacy of GM or LVF versus -loaded NHs (NH/GM or NH/LVF, 80 
respectively) was explored. These two antibiotics were selected as they have different intracellular 81 
pathways: GM is a lysosomal drug[10], whilst LVF is a cytosolic one[8a]. GM is typically used in topical 82 
preparations and can be employed to treat skin infections, whilst LVF remains among the most 83 
active oral antimicrobials.  84 
 85 
2. Results and Discussion 86 
2.1.   Development and characterization of NH/GM and NH/LVF 87 
In order to generate NHs, HA carboxyl groups were functionalized with a small hydrophobic 88 
molecule, cholesterol (CH) [29]. In a previous work, the soft nature, the swelling ability, the spherical 89 
shape and size of HA-CH NHs in both dry and aqueous environments (by using Atomic Force 90 
Microscopy and Transmission Electron Microscopy techniques) were showed[30]. These 91 
nanoparticles evidenced the ability to absorb a high amount of water and to swell in aqueous media, 92 
thus showing the typical properties of NHs [31, 32]. As HA chains are chemically modified with a 93 
hydrophobic moiety (CH), the resulting amphiphilic polymer is able to self-assemble in aqueous 94 
environment and spontaneously forms physically cross-linked tri-dimensional networks which are 95 
characterized by internal hydrophobic domains and hydrophilic outer chains.  Depending on the 96 
degree of functionalization and on the polymer molecular weight, these aggregates may form 97 
regular nano-structures, after suitable treatments such as sonication or autoclaving.  98 
In this respect, it was already shown that autoclaving (121°C, 20 min) represents a fast and 99 
reproducible one-pot method for directly achieving sterile and drug-loaded NHs [33]. In this way, 100 
both sterile NH/GM and NH/LVF were obtained after autoclaving (Figures 1 and 2). Nano-systems 101 
were purified from the free antibiotics using a size exclusion chromatography (SEC) column; drug 102 
loading (DL, %) and loading efficiency (LE, %) were studied with an ultra-performance liquid 103 
chromatography (UPLC) coupled with a mass-spectrometer (NH/GM) and with a UV-Vis 104 
spectrometer (NH/LVF). The amount of entrapped drug is reported in Table 1 and shows that GM 105 
loading was higher than that of LVF; this may be due to the amino groups of the GM sugar rings, 106 
which exhibit a net positive charge under physiological conditions (pKa values of GM amine groups 107 
range from 5.6 to 9.5), establishing strong electrostatic interactions with the negatively charged HA 108 
chains. In contrast, LVF exists as a zwitterion at pH 6.0-7.5, leading to weaker interactions with NHs 109 
and, thus, lower encapsulation values. NH/GM and NH/LVF were characterized in terms of mean 110 
diameter, PDI and ζ-pot (as summarized in Figure 1A, B, C and 2A, B, C), showing average sizes of ~ 111 
250 nm (NH/GM) and ~ 350 nm (NH/LVF). It was necessary the use of different solvents for the 112 
formulation of NH/GM and NH/LVF; pH values lower than 7 were not suitable for the formation of NH/GM 113 
as a precipitate was found after the autoclaving process (possible due to the strong electrostatic interactions 114 
occurring between GM and HA, which prevent the NHs formation by self-assembling). Whilst, less LVF was 115 
loaded into NHs at neutral pH compared to that loaded in double-distilled water (pH=5). This result can be 116 
ascribed to the zwitterionic nature of LVF. Therefore, to maximize the concentration of antibiotics loaded in 117 
the NHs a different solvent for each antibiotic was used. As expected, an increase in the amount of 118 
loaded GM led to a decrease of the ζ-pot net value of NHs (due to the positively charged GM) 119 
compared to that of the unloaded NHs. Indeed, the GM DL% of 40 ± 1%, 35.1 ± 2.8% and 30.7 ± 2% 120 
(w/w, %) led to a ζ-pot change of 49%, 24% and 20%, respectively, compared to that of free NHs, 121 
evidencing a GM concentration-dependent effect. Loaded LVF affected NHs ζ-pot to a lesser extent. 122 
Moreover, both NH/GM and NH/LVF stored at -20°C or freeze-dried as solid powders, retained their 123 
mean diameter and PDI when defrosted and re-hydrated. For preserving the starting NH/GM and 124 
NH/LVF properties, it was necessary to add dextrose before freeze-drying (Figure 1A and B). The 125 
NHs freeze-dried powder ensures the long-term storage of the nano-formulations, as the stability 126 
of the aqueous suspensions of NHs and the loaded drugs is rather limited. The antimicrobial activity 127 
of NH/LVF freeze-dried powder was already studied against intracellular S. aureus and P. 128 
aeruginosa[27], evidencing the storage method is able to retain the whole activity of the nano-129 
formulation. Furthermore, the NHs freeze-dried powder could be mixed with appropriate materials 130 
(e.g. carbopol), at suitable concentrations, in order to obtain formulations for topical 131 
administrations. Figs. 1 and 2 also show that liquid samples can be frozen, retaining their size and 132 
PDI and assuring a long-term storage without the addition of any additive. 133 
Among the prepared samples, NH/GM and NH/LVF with the starting 1:1 wt. ratio (formulations 134 
written in bold in Table 1) showed the best properties and loading efficiency, therefore they were 135 
selected for subsequent experiments. To assess the stability of loaded NHs in aqueous 136 
environments, drug release studies (Figure 1D and 2D) were performed in double-distilled water 137 
(pH ~ 5 similar to that of the human skin). Results showed that only 10% (% w/w) of loaded GM was 138 
released from NHs in 24 h, evidencing the high stability of the nano-formulation. Longer time points 139 
were also checked over one week (data not shown), but no changes were observed in the release 140 
profile. This behaviour can be explained by taking into account that the electrostatic interactions 141 
between the negatively charged NHs and the positively charged GM are very strong at low ionic 142 
strength. However, some degradation mechanisms should occur in ‘in vitro’ or ‘in vivo’ (e.g. specific 143 
enzymes such as HAase and esterase, acidic pH and free radicals), enhancing the GM release from 144 
the NHs. In contrast, 48% (% w/w) of loaded LVF was released over 24 h in the same conditions; this 145 
result can be ascribed to weaker interactions within the NHs. 146 
 147 
2.2. Cell viability of HaCaT 148 
To determine the effects of antibiotics-loaded NHs on cell viability, HaCaT cells were incubated with 149 
NH/GM or NH/LVF or their antibiotic-free controls over 48 h. Both MTT (Figure 3A and C) and trypan-150 
blue (Figure 3B and D) assays showed that NHs preparations were not toxic to HaCaT, as neither 151 
HaCaT metabolism nor vitality was significantly affected by any of the tested concentrations after 152 
48 h (Figure 3).  153 
 154 
 155 
2.3. Antibacterial activity of NH/GM and NH/LVF against extracellular and intracellular 156 
S.aureus 157 
To ensure the NHs encapsulation do not enhance or inhibit antimicrobial activity, the MIC and the 158 
minimum bactericidal concentration (MBC) of NHs alongside free GM and LVF, NH/GM and NH/LVF 159 
were determined; figure 4A shows the mean MIC and MBC values. Free NHs did not show any 160 
antimicrobial activity and incorporation of GM or LVF into NHs did not affect their antibacterial 161 
activity against extracellular S. aureus. The efficacy of the nano-formulations against intracellular S. 162 
aureus was then assessed by enumerating viable intracellular bacteria from infected HaCaT treated 163 
with NH/GM, NH/LVF or their controls, in conditions which did not affect the viability of HaCaT cells, 164 
by using the following concentrations: c = 46.8 µg/mL (GM) and c = 117 µg/mL (NHs) for the NH/GM 165 
system and at c = 35.1 µg/mL (LVF) and c = 307 µg/mL (NHs). Antibiotic concentrations tested were 166 
3 fold greater than the MIC/MBC to ensure eradication of viable bacterial cells. After 2 h of 167 
incubation, NH/GM and NH/LVF and their controls were not effective against intracellular S. aureus 168 
(Figure 4B). After 5 h of incubation both free GM and NH/GM showed significant antimicrobial 169 
activity against the intracellular S. aureus (p<0.05); however, when compared to free GM, NHs did 170 
not enhance GM activity intracellularly. In contrast, LVF activity was highly enhanced by NHs 171 
(p<0.005) when compared to that of free LVF (Figure 4B).  172 
 173 
2.4. Uptake and intracellular fate of HA-CH NHs in HaCaT 174 
Rhodamine B-isothiocyanate (rhod) dye was covalently linked to the hydroxyl groups of NHs and the 175 
obtained fluorescent NHs were employed for studying their binding/internalization kinetics and 176 
intracellular fate into HaCaT by flow cytometry and fluorescence microscopy. Flow cytometry 177 
analysis evidenced that HaCaT incubated for 30 min with rhod-NHs showed a significant increase in 178 
fluorescence intensity, indicating a quick binding/uptake of NHs within the cells. HaCaT fluorescence 179 
steadily increased over the time and 4 h represented the time point at which the highest signal was 180 
detected, followed by a plateau up to 24 h (Figure 5A). Moreover, HaCaT cells showed increased 181 
fluorescence in a dose-dependent manner with rhod-NHs concentrations up to 100 µg/mL after 4 h 182 
of incubation (Figure 5B). 183 
ApoTome analysis showed NHs located into vesicle-like structures, those with a diameter of 184 
approximately 0.3 µm close to the plasma membrane and those in larger vesicles with diameter up 185 
to 1.5 µm close to the nucleus, suggesting an intracellular location of NHs (Figure 6).  Interestingly, 186 
Tammi et al. (2001) had a similar outcome using free HA in rat epidermal keratinocytes [19a]. To 187 
determine the intracellular fate of NHs and explore the possibility of their co-localization with 188 
lysosomes, HaCaT were then incubated up to 24 h with the nano-system and stained with ‘Lyso-189 
tracker Green DND-26’ (Figure 7). At 1 h a limited number of NHs was located in lysosomes; 190 
however, from 4 to 24 h a strong co-localization occurred (***P value < 0.005) compared to that at 191 
1 h, showing the highest Pearson correlation coefficient value [34] (0.94) at 4 h. NHs in lysosomes 192 
were still evident up to 24 h, although co-localization was weaker than that found at 4 h (~ 0.7) 193 
(Figure 7); no significant differences were found in the time points ranging from 6 to 24 h. 194 
Since a previous work showed that LVF predominantly accumulates in the cytosol, it is plausible that 195 
NHs are able to change the intracellular fate of LVF (from cytosol to lysosome), delivering the 196 
antibiotic to the intracellular location of S. aureus (Figure 8), thus enhancing its intracellular 197 
antimicrobial activity (Figure 4B). On the other hand, GM, an antibiotic that predominantly 198 
accumulates in lysosomes, showed a significant antibacterial activity without the presence of NHs. 199 
These results strongly suggest that therapeutics that are able to accumulate in lysosomes might be 200 
more effective against intracellular S. aureus compared with those that accumulate in other cell 201 
compartments (e.g. cytosol), evidencing that: I) sub-cellular targeting could be necessary for 202 
eradicating the intracellular pathogen; II) lysosomal nanoparticles (e.g. HA-CH NHs) might be 203 
suitable for enhancing the antibacterial activity of such antibiotics against the intracellular S. aureus 204 
in human keratinocytes.  205 
 206 
3. Conclusion 207 
We have shown that self-assembled NHs can be loaded with GM or LVF antibiotics by means a fast 208 
one-step sterile cycle using an autoclave (121°C for 20 min). NH/GM and NH/LVF show mean 209 
diameters of approximately 250 and 350 nm, respectively; both nano-formulations do not affect 210 
viability of HaCaT cells at all tested concentrations over 48 h and display the same MIC and MBC 211 
values as free antibiotics against extracellular S. aureus. However, intracellularly, the antibacterial 212 
activity of LVF was highly enhanced by NHs. As we have demonstrated that NHs co-localize with 213 
lysosomes of HaCaT cells and it is known that free LVF predominantly accumulates in the cytosol, 214 
these results strongly suggest that NHs may be able to change the intracellular fate of LVF from 215 
cytosol to lysosome, thereby targeting intracellular S. aureus. Indeed, GM, an antibiotic that 216 
predominantly accumulates in lysosomes, shows significant intracellular activity without the 217 
employment of NHs. To conclude, this research demonstrates that lysosomal formulations may be 218 
more effective against S. aureus in keratinocytes compared with formulations that accumulate in 219 
other cell compartments (e.g. cytosol), opening new avenues for HA-based NHs treatments of 220 
persistent S. aureus skin infections.   221 
 222 
4. Experimental section  223 
Materials: Hyaluronan tetrabutylammonium salt (HA-TBA+, Mw = 2.2 x 105) was purchased from 224 
Contipro (Dolní Dobrouč, Czech Republic). Cholesterol (CH), 4-bromobutyric acid, N-methyl-2-225 
pyrrolidone (NMP), N-(3-dimethylaminopropyl)-N’-(ethylcarbodimide hydrochloride) (EDC∙HCl), 226 
gentamicin sulfate (GM), levofloxacin (LVF), 4-(dimethylamino)pyridine (DMAP), phosphate 227 
buffered saline tablets, dextrose, dimethyl sulfoxide ACS reagent ≥99,9%, trypsin-EDTA solution 228 
10X, formaldehyde solution for molecular biology ≥36.0%, 4′,6-diamidino-2-phenylindole dilactate 229 
(DAPI) for nuclei staining, Mowiol® 4-88, rhodamine B isothiocyanate, Hanks’ Balanced Salt solution 230 
(HBSS) and L-glutamine were purchased from Sigma-Aldrich (Milan, Italy). Dulbecco’s Modified 231 
Eagle Medium (DMEM 1X) was purchased from Gibco® brl life technologiesTM inc., Grand Island (NY, 232 
USA). Lyso-Tracker Green DND-26, Invitrogen™ Molecular probes® were purchased from Thermo 233 
Fisher Scientific (Monza, Italy). Triton® X-100, albumin from bovine serum, ammonium formate, 234 
trypan blue solution were purchased from Biochemica Fluka, Sigma-Aldrich (Milan, Italy). 235 
Nitrotetrazolium blue chloride (MTT, CellTiter 96® Non-Radioactive Cell Proliferation Assay) was 236 
purchased from Promega (Milan, Italy). Acetonitrile for HPLC and ACS water suitable for 237 
UPLC/UHPLC instruments were purchased from VWR (Milan, Italy).  238 
Bacterial strains: Staphylococcus aureus NCTC 12973 was obtained from Public Health England 239 
Southampton, UK. Stock cultures were stored at -80°C using Protect cryobead vials (Technical 240 
Service Consultants Ltd, Heywood UK). Prior to experiments bacterial cultures were revived by 241 
transferring cryobead/s onto fresh sterile Mueller-Hinton agar and incubated at 37°C for 24 h. 242 
Dehydrated bacteriological media were obtained from Oxoid (Basingstoke, Hampshire, U.K.) and 243 
reconstituted according to the manufacturer’s instructions. Bacterial growth media were sterilized 244 
at 121°C, 15 psi for 15 min prior to use. 245 
General cell culture: The human keratinocyte cell line (HaCaT) was spontaneously immortalized from 246 
primary keratinocytes[35] and cultured in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM; 247 
EuroClone, Milan, Italy) supplemented with 10% (v/v) fetal bovine serum (FBS) and 4 mM glutamine 248 
at 37°C in a humidified atmosphere with 5% CO2. Cells were grown to 70-80% semi-confluence, 249 
according to each experimental setting and treated with free or loaded antibiotics at several time 250 
points and concentrations. All experiments contained untreated cells (PBS) processed in parallel as 251 
negative control. 252 
 253 
Synthesis of cholesterol-Br-butyric derivative (CH-Br): CH-Br synthesis was carried out as previously 254 
described [29]. Briefly, 500 mg of CH (1.3 x 10-3 mol) were solubilized in 5 mL of CH2Cl2 and added to 255 
79 mg of DMAP (6.5 x 10-4 mol); the solution was stirred for 15 min at 25°C. Meanwhile, 648 mg of 256 
4-bromobutyric acid (3.9 x 10-3 mol) and 744 mg of EDC∙HCl (3.9 x 10-3 mol) were solubilized in 5 mL 257 
of CH2Cl2; the two solutions were then mixed and kept at 25°C with magnetic stirring, overnight. 258 
Reaction products were checked with silica gel TLC (cyclohexane : ethylacetate, 85:15) and then 259 
washed once with 50 mM NaOH and HCl and three times with bi-distilled water. The solution was 260 
firstly dried with anhydrous Na2SO4 and then with vacuum evaporation. The crude product (powder) 261 
was finally purified with a silica column (eluent, cyclohexane : ethylacetate, 98.5:1.5); 310 mg of 262 
pure CH-Br were obtained (yield 60%, % w/w). 263 
 264 
Synthesis of hyaluronan-cholesterol amphiphilic polymer (HA-CH): HA-CH synthesis was carried out 265 
as previously reported [29]. 200 mg of HA-TBA+ (Mw = 2.2 x 105) were added to 10 mL of NMP and the 266 
sample was kept at 25°C for 5 h with magnetic stirring; then, 34.3 mg of CH-Br, previously solubilized 267 
in 2 mL of NMP, were added and the reaction was allowed to proceed for 48 h at 38°C with magnetic 268 
stirring. Then, 2 mL of NaCl (saturated solution) were added to the polymer solution and the mixture 269 
was left under stirring for 30 min to allow the exchange of the Na+ with TBA+ ions. The reaction 270 
product was precipitated in acetone (4 times the reaction volume), left for 1 h at 4°C, isolated, re-271 
suspended in bi-distilled water and finally dialysed against water (cellulose membrane tubing, Mw 272 
cut-off: 1.2-1.4 x 104, Sigma-Aldrich, Darmstadt, Germany) until constant conductivity was reached. 273 
Sample was freeze-dried with a “Modulyo 4K” Edwards High Vacuum instrument, equipped with an 274 
Edwards pump, operating at 0.2 atm and at −40°C, yielding 354 mg of white solid (71% mass 275 
recovery). Theoretical degree of functionalisation (DF) was 15% (% mol/mol, corresponding to mol 276 
of CH per mol of HA repeating unit). 277 
 278 
Preparation and characterization of GM or LVF-loaded HA-CH nanohydrogels (NH/GM or NH/LVF):  279 
2 mg of HA-CH were dispersed in 1 mL of Milli-Q water (2 mg mL-1) overnight with magnetic stirring 280 
at 25°C. Then 1 mL PBS (pH=7.4) and 0.1 mL of GM solution (10, 5 or 2.5 mg mL-1), or 1 mL Milli-Q 281 
water and 0.1 mL of LVF solution (10, 5 or 2.5 mg mL-1) (corresponding to 1:1, 1:0.5 and 1:0.25 HA-282 
CH:GM or HA-CH:LVF wt. ratio) were added. Samples were then autoclaved for 20 min at 121°C, 283 
leading to NH/GM or NH/LVF formation. NH/GM or NH/LVF suspensions were purified from the free 284 
antibiotics through SEC. SEC was performed using Econo-Pac chromatography columns (Bio-Rad, 285 
Segrate, Italy) packed with Bio-Gel® P-10 (polyacrylamide with an exclusion limit range of 1.5-20 x 286 
103, Bio-Rad, Segrate, Italy). 1 mL of NH/GM or NH/LVF mixtures was loaded into SEC and eluted 287 
with 10 mL PBS or water, respectively, at 25°C and atmospheric pressure.   288 
 289 
Dynamic Light Scattering (DLS): hydrodynamic diameter (Z-average size), size distribution, 290 
polydispersity (PDI), and ζ-potential of NH/GM or NH/LVF were measured by Dynamic Light 291 
Scattering (DLS) at 25 °C by using a Zetasizer Nano ZS instrument (Model ZEN3690, Malvern 292 
Instruments) equipped with a solid state HeNe laser (λ = 633 nm) at a scattering angle of 173°. Size 293 
measurement data were analyzed by using the general purpose algorithm. The electrophoretic 294 
mobility of the samples was converted in ζ-potential by using the Smoluchowski equation. 295 
Hydrodynamic diameter and PDI of freeze-thawed or freeze-dried NH/GM or NH/LVF were also 296 
studied; empty NHs were prepared as controls. Each experiment was performed in triplicate (n=3). 297 
 298 
Quantification of entrapped GM or LVF into NHs: 299 
A) UPLC coupled to mass spectrometry (LC-MS) analysis: the amount of GM entrapped into NHs 300 
was checked with a Waters Acquity H-Class UPLC liquid chromatography-mass spectrometer 301 
(Waters, Milford, MA, USA), equipped with a quaternary solvent manager (QSM), a sample 302 
manager with flow through needle system (FTN) and a single-quadrupole mass detector with 303 
electrospray ionization source (ACQUITY QDa). Free GM solutions were diluted with water, 304 
filtered with 0.22 µm regenerated cellulose membrane filters (Sartorius Italy s.r.l., Monza, 305 
Italy) and injected into a Waters BEH Shield C18 column (50 mm × 2.1 mm i.d., 1.7 μm particle 306 
size). Samples were eluted using an isocratic 10 mM HCOONH4 mobile phase (pH = 3) at a 307 
flow rate of 0.5 mL min-1 and column temperature of 25°C. Mass spectrometry detection 308 
was performed in positive electrospray ionization mode (ESI), using nitrogen as nebulizer 309 
gas. Three m/z values (478, 464 and 450) corresponding to the three [M+H]+ GM chemical 310 
species were monitored in single ion recognition mode (SIR). Capillary and cone voltage were 311 
set to  0.8 kV and 15 V; ion source and probe temperatures were adjusted to 120°C and 312 
600°C. A GM calibration curve was calculated at the concentration range of 7.5-125 µg mL-1 313 
(R2 = 0.98, n= 3).  314 
B) UV-Vis spectrometry analysis: the amount of LVF entrapped into NHs was assessed by using 315 
a Perkin-Elmer double beam “Lambda 3A” model. Analyses were performed at 25°C, using 1 316 
mm quartz cuvettes (Hellma Analytics, Milan, Italy). LVF water solutions were detected at 317 
286 nm. A LVF calibration curve was built at the concentration range of 16-200 μg mL-1 (R2 = 318 
0.999, n=5). The amount of entrapped GM or LVF was calculated by subtracting the amount 319 
of unloaded GM or LVF from the starting total amount of drugs. Each experiment was 320 
performed in triplicate (n=3). 321 
Drug loading (DL%) and loading efficiency (LE%) of both GM and LVF were calculated using the 322 
following equation (1) and (2): 323 
 324 
𝐷𝐿% =  ௪௘௜௚௛  ௢௙ ௟௢௔ௗ௘ௗ ௗ௥௨௚
௪௘௜௚  ௢௙ ௧௢௧௔௟ ௗ௥௨௚
 𝑥 100       (1) 325 
 326 
𝐿𝐸% =  ௪௘௜  ௢௙ ௟௢௔ௗ௘ௗ ௗ௥௨௚
௪௘௜௚௛௧ ௢௙ ௣௢௟௬௠௘௥
 𝑥 100       (2) 327 
 328 
 329 
In vitro release studies of GM or LVF from NHs: 1 mL of purified NH/GM or NH/LVF (1:1 starting wt. 330 
ratio) was put into a membrane tube (Mw cut-off 1.2-1.4 x 104) and dialysis was performed against 331 
15 mL bi-distilled water for 24 h, at 37°C; at specific time points 3 mL solution were taken off and 332 
replaced with 3 mL of bi-distilled water. Samples were then injected into UPLC-MS or analysed with 333 
UV-Vis spectrometer for quantifying the amount of released GM or LVF from NHs, respectively. Each 334 
experiment was performed in triplicate (n=3). 335 
 336 
Cell viability assays: HaCaT viability was tested in parallel with 3-(4,5-dimethylthiazol-2-yl)-2,5-337 
diphenyltetrazolium bromide metabolic assay (MTT assay) and trypan blue exclusion method, by 338 
counting both dead and living cells. 339 
A) MTT test: 100 µL HaCaT (5,000 cells/well in complete DMEM) were seeded in a 96-well plate 340 
(Falcon™ Polystyrene Microplates, Thermo Fisher Scientific, Monza, Italy) and incubated for 341 
24 h. Cell monolayers were then added to 25 µL of samples (free NHs, GM or LVF, NH/GM 342 
or NH/LVF in PBS pH=7.4) at specific final NHs concentrations (ranging from 18-500 and 37-343 
1000 µg mL-1 for NH/GM and NH/LVF respectively, df: 1:3) and incubated for 24 and 48 h. As 344 
negative control, cells received 25 µL PBS. Then, medium was removed, cells were gently 345 
washed with PBS and 100 µL complete DMEM were added. 20 µL MTT solution (Promega, 346 
Italy, Milan) were added and HaCaT were incubated for 2 h. Supernatants were gently 347 
removed and formazan crystals were solubilised with 100 µL DMSO. Absorbance was 348 
checked at 570 nm with a reference at 690 nm, using an Appliskan microplate reader 349 
(Thermo Scientific, Vantaa, Finland). Each experiment was performed on sixteen wells (n=3). 350 
Results were processed using SkanIt 2.3 Software.  351 
B) Trypan Blue exclusion method: 1.5 mL HaCaT (167,000 cells/well in completed DMEM) were 352 
seeded in a 6-well plate and incubated for 24 h. 0.375 mL of free NHs or NH/GM or NH/LVF 353 
in PBS at the final NHs concentration of 500 or 1000 µg mL-1 (NH/GM or NH/LVF respectively) 354 
were then added to the cells, which were incubated for 24 and 48 h. As negative control, 355 
cells received 0.375 mL PBS. Subsequently, medium (1.875 mL) was taken off and stored into 356 
eppendorf tubes (Primo® boil-proof microcentrifuge tubes, EuroClone spA, Milan, Italy); 357 
then, wells were gently washed with 1 mL PBS and 0.6 mL 0.5% trypsin were added. Cells 358 
were allowed to detach for 10 minutes at 37°C and then added to the previously removed 359 
1.875 mL DMEM. 80 µL cell suspensions were mixed with 80 µL 0.4% trypan blue solution 360 
and cells were counted with a Primovert microscope (Carl Zeiss Microimaging GmbH, 361 
Gottingen, Germany) in a Neubauer chamber. Each experiment was performed in triplicate 362 
(n=3). 363 
 364 
Determination of MICs and MBCs: 365 
The MIC and MBC were determined for axenic planktonic populations of S. aureus using the 366 
microdilution method [36]. Briefly, 100 µL double strength Mueller-Hinton broth was dispensed in 367 
wells of the first column of a flat bottom 96-well microtiter plate. Stationary phase cultures of S. 368 
aureus grown in Mueller-Hinton broth, were adjusted in fresh sterile Mueller-Hinton broth to give 369 
a cell density of c. 2 x 106 CFU mL-1. Within 30 minutes of preparation inocula were dispensed (100 370 
µL) into the remaining wells the 96-well plate. Stock solutions of free GM, LVF, NHs or NH/GM or 371 
NH/LVF were prepared in sterile PBS and dispensed (100 µL) into the first column of the microtiter 372 
plate. Doubling dilutions of samples were then undertaken across the plate (100 µL). Plates were 373 
incubated at 37°C for 24 h. The MIC endpoint was determined as the lowest concentration of 374 
antimicrobial that prevented visible growth. To determine the MBC, aliquots (10 μL) from wells 375 
exhibiting no turbidity were spot plated onto sterile Mueller-Hinton agar. After incubation at 37°C, 376 
the MBC endpoint was determined as the lowest concentration that resulted in no visual growth of 377 
colonies after 24 h of incubation. Each experiment was performed in triplicate (n=3). 378 
 379 
Cell infection and assessment of intracellular activity of NH/GM or NH/LVF: To assess the efficacy of 380 
free or loaded GM or LVF on intracellular bacteria, HaCaT cell monolayers were grown to 70-80% 381 
semi-confluence by seeding 1.5 x 105 cells in 1 mL of complete DMEM (2 mM glutamine) in 24-well 382 
plates and incubating for 18 h. Mid-log phase cultures of S. aureus were washed twice with sterile 383 
PBS and culture densities adjusted in sterile, FCS free DMEM to give a cell density of c. 100 CFU/cell 384 
(100 MOI). Growth medium was removed and HaCaT cells were washed with sterile PBS and FCS 385 
free medium was added to each well.  Aliquots of adjusted bacterial cultures were added to cells 386 
and plates were incubated for a further 3 h. In order to remove any extracellular bacteria, cell 387 
culture media were then removed from wells and 1 mL fresh serum free media containing X2 MIC 388 
gentamicin added. Plates were further incubated for 1 h. Medium was removed and HaCaT cells 389 
were washed twice with sterile PBS. Free GM or LVF and their nano-formulations were reconstituted 390 
in sterile PBS and diluted to the desired concentration in fresh serum free DMEM in order to have 391 
3X MIC value (final concentration of drugs in the well). 1 mL aliquots of treatments were then added 392 
to cells and plates were incubated for either 2 or 5 h. After incubation, cells were washed twice with 393 
PBS and lysed with 0.025% Triton X for 10 min. To enumerate viable bacteria, lysates were harvested 394 
and serially diluted in sterile PBS and inoculated onto Mueller-Hinton agar. Agar plates were 395 
incubated for > 16 h and viable counts performed. All experiments contained non-infected cell 396 
monolayers processed in parallel as a sterile control and infected cell monolayers processed with 397 
serum free media in the absence of any test treatment as a positive control. Each experiment was 398 
performed in triplicate (n=3). 399 
 400 
Synthesis of fluorescent NHs (rhod-NHs): 1.5 mg mL-1 HA-CH polymer in bi-distilled water was left 401 
with magnetic stirring overnight at 25°C. The sample was placed in an autoclave (121°C for 20 min) 402 
where NHs were allowed to form. Rhodamine B-isothiocyanate (rhod) was previously solubilized in 403 
DMSO at a concentration of 9 mg mL-1 and then added to NHs suspension (8 µL for 1 mg of polymer, 404 
corresponding to a DF of 6.3%; % mol/mol). The reaction mixture was left for 5 h at 25°C in the dark, 405 
following which it was dialysed against water until constant conductivity was reached and then 406 
freeze-dried. The final DF% was assessed through UV-Vis analysis: sample was solubilized in DMSO 407 
and checked at 550 nm at 25°C. A rhod calibration curve was built at the concentration range of 8.5-408 
125 µg mL-1 in DMSO. DF corresponded to 1.3% (mol of rhod per mol of HA-CH repeating unit). 409 
 410 
Flow cytometry analysis: Cell binding/uptake kinetics of fluorescent NHs was studied with a BD 411 
Accuri C6, BD 254 Bioscences (Erembodegem, Belgium) flow cytometer equipped with a 488 nm 412 
excitation laser and a 585/40 nm band-pass filter (FL2 channel). For each sample 50,000 events were 413 
collected. 1 mL HaCaT cell suspension (67,000 cells/well in complete DMEM) was seeded in 12-well 414 
plates and incubated for 48 h. Cells were washed three times with PBS, 1.5 mL of complete DMEM 415 
added and treated with 0.25 mL of 0.5 mg mL-1 rhod-NHs in PBS (corresponding to a final 416 
concentration of 0.10 mg mL-1) at specific time points, over 24 h. Medium was removed, cells were 417 
washed three times with PBS, allowed to detach with 0.25 mL trypsin and finally added to 0.75 mL 418 
complete DMEM.  Cell suspensions were centrifuged in eppendorf tubes for 8 min at 1,200 rpm at 419 
4°C. Supernatants were removed and pellets were washed with 1 mL HBSS solution and centrifuged 420 
again. Pellets were re-suspended in 0.5 mL HBSS and red fluorescence (rhod) was detected with a 421 
flow cytometer. HaCaT cells were also treated with 0.25 mL of rhod-NHs (final concentrations 10, 422 
50, 100, 500 µg mL-1) at a fixed time point (4 h) by following the same procedure and then analysed 423 
with a flow cytometer. As a negative control, cells received 0.25 mL PBS. Results are expressed as 424 
median fluorescence intensity. (n=3). A dot plot was built by plotting Forward scatter (FSC-H) versus 425 
Side scatter (SSC-H) and the gate was constructed excluding cell debris. Each experiment was 426 
performed in triplicate (n=3). 427 
 428 
Cell imaging:  429 
ApoTome microscope: Immunofluorescence signal of fluorescent NHs was analysed by recording 430 
stained images using an Axio Observer Z1 inverted microscope, equipped with an ApoTome.2 431 
System (Carl Zeiss Inc., Ober Kochen, Germany). The ApoTome system provides an optical section 432 
of fluorescent samples, calculated from three images with different grid positions without time lag. 433 
Digital images were acquired with the AxioCam MRm high resolution digital camera (Zeiss) and 434 
processed with the AxioVision 4.8.2 software (Zeiss). ApoTome optical sectioning images of 435 
fluorescent NHs were recorded under 40x/0.75 objective (Zeiss). Pearson’s correlation coefficient 436 
[32] was used to quantify the degree of colocalization between fluorescent NHs and Lyso-Tracker 437 
Green DND-26 staining in a series of 0.5 nm sequential sections, under an immersion oil 63x/1.25 438 
objective (Zeiss). Pearson’s correlation coefficient was calculated using the AxioVision 4.8.2 439 
software (Zeiss), analyzing a minimum of 40 cells randomly taken from each slide from three 440 
independent experiments. Images were obtained from the 2D reconstruction of selected serial 441 
optical sections. 442 
 443 
Cellular uptake micro-graphs: 1.5 mL HaCaT cells (167,000 cells/well in complete DMEM) were 444 
seeded on microscope slides (Prestige micro cover glass 22 X 22 mm, Syntesys Disposable Labware, 445 
Padova, Italy) in a 6-well plate and allowed to adhere for 48 h. Then, cells were washed three times 446 
with PBS, 1.5 mL of complete DMEM added and incubated with 0.375 mL of 0.5 mg mL-1 rhod-NHs 447 
in PBS (corresponding to a final concentration of 0.1 mg mL-1) or free rhod previously solubilised in 448 
DMSO (final concentration of 7.2 µg mL-1). After 4 h, medium was removed and cells were washed 449 
three times with PBS. Cells were fixed with 2% (v/v) formaldehyde (2 mL, 10 min), washed three 450 
times with PBS and incubated with Triton X-100 (0.1%, v/v, 2 mL, 5 min). Cells were washed three 451 
times with PBS and nuclei were stained with DAPI reagent (1 µg mL-1, 1 mL for 1 min). Finally, cells 452 
were washed again and 8 µL Mowiol were added; slides were allowed to dry and fix overnight at 453 
25°C on StarFrost® microscope slides (Braunschweig, Germany). Samples were then analysed with 454 
the ApoTome microscope. 455 
 456 
Lysosomal co-localization in living cells: 1.5 mL HaCaT (167,000 cells/well in complete DMEM) were 457 
seeded on microscope slides in a 6-well plate and allowed to adhere for 48 h. Cells were washed 458 
three times with PBS, 1.5 mL of complete DMEM added and incubated with 0.375 mL of 0.5 mg mL-459 
1 rhod-NHs (corresponding to a final concentration of 0.1 mg mL-1). After several time points (from 460 
0.5 to 24 h) slides were washed three times with PBS, 1.5 mL of complete DMEM added and finally 461 
incubated with 1 mL of Lyso-Tracker Green DND-26 staining (final concentration of 200 nM) for 3 462 
min at 37°C. Images were immediately recorded on living cells with the ApoTome microscope. 463 
Results were obtained from three independent experiments, each derived from eight images. 464 
 465 
Statistical analysis:  466 
Cell infection and assessment of intracellular activity of NH/GM or NH/LVF.  467 
Viable cell counts were calculated using three biological replicate count data (each derived from 468 
three technical replicate data). All data were Log10 transformed and are expressed as the mean 469 
value ± standard deviation. Statistical significance was determined using biological replicate data 470 
(n=3) with Mann-Whitney test by using SPSS 20 Software. P values < 0.05 were considered 471 
significant. Asterisk denote statistically significant differences (*P<0.05). 472 
Cell viability and cell count assays 473 
Viable HaCaT (MTT and trypan blue) were calculated using three biological replicates (each derived 474 
from sixteen wells). Cell viability and cell growth were normalized to the negative control (untreated 475 
cells that received PBS), whilst the cell death was normalized to the total amount of cells. All data 476 
are expressed as the mean value ± standard deviation. Statistical significance was determined using 477 
sixteen wells (n=3) with One-way ANOVA analysis in Prism (GraphPad 5.0 Software, Inc., La Jolla, CA, 478 
USA). Differences between groups were determined by a Turkey’s multiple comparison test. 479 
Asterisks denote statistically significant differences (*P<0.05; **P<0.01; ***P<0.005). 480 
Co-localization experiments 481 
Pearson’s correlation coefficient was used to quantify the degree of co-localization between 482 
fluorescent NHs and Lyso-Tracker Green DND-26 staining, which was calculated using the AxioVision 483 
4.8.2 software (Zeiss) and expressed as the mean value ± standard deviation.   Results were obtained 484 
from three independent experiments, each derived from eight images.  Statistical significance was 485 
determined using One-way ANOVA analysis. 486 
 487 
Graphs and Figures: All graphs and figures were processed with OriginPro 2016 and CorelDraw 488 
Graphics Suite X8 Softwares. 489 
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Figure 1. Mean diameter (A) and PDI (B) of starting, freeze-thawed and freeze-dried NH/GM. HA-CH/GM mixtures 
were prepared at several wt. ratios (ranging from 1:0.25 to 1:1 of HA-CH and GM, respectively) in 50 mM PBS (pH=7.4) 
and then autoclaved at 121°C for 20 min. Unloaded GM was discarded by purification through a SEC column. (C) ζ-pot 
of NH/GM samples. (D) Release of GM from NHs over 24 h at 37°C in bi-distilled water. Released GM was analysed 
though UPLC coupled with mass-spectrometer. All data are expressed as the mean value ± standard deviation. Results 
were obtained in triplicate (n=3).  
 
 
 
Figure 2. Mean diameter (A) and PDI (B) of starting, freeze-thawed and freeze-dried NH/LVF. HA-CH/LVF mixtures 
were prepared at several wt. ratios (ranging from 1:0.25 to 1:1 of HA-CH and LVF, respectively) in bi-distilled water 
and then autoclaved at 121°C for 20 min. Unloaded LVF was discarded by purification through a SEC column. (C) ζ-pot 
of NH/LVF samples and (D) release of LVF from NHs over 24 h at 37°C in bi-distilled water. LVF was detected with UV-
Vis spectrometer.  All data are expressed as the mean value ± standard deviation. Results were obtained in triplicate 
(n=3). 
 
 
 
 
 
  
Figure 3. Viability of HaCaT: MTT (A and C) and trypan blue (B and D) assays were performed on cells cultured in 
completed DMEM, incubated for 24 and 48 h with NH/GM (A and B) and NH/LVF (C and D). Only samples with the 
starting 1:1 wt. ratio (HA-CH:drug) were tested. Results were obtained from three independent experiments (each 
derived from sixteen wells). All data are expressed as the mean value ± standard deviation. MTT and cell growth 
results were normalized to the control (untreated cells that received PBS), whilst the cell death was normalized to the 
total amount of cells. Statistical significance was determined with One-way ANOVA analysis. Differences between 
groups were determined by a Turkey’s multiple comparison test. No significant differences were detected. 
 
 
 
  
Figure 4. (A) MIC and MBC of NH/GM, NH/LVF and their controls against planktonic S. aureus. Plates were incubated 
for 24 h. The MIC endpoint was determined as the lowest concentration of antimicrobial at which there was no visible 
growth; the MBC endpoint was determined as the lowest concentration that resulted in no visual growth of colonies 
after 24 h of incubation. (B) Intracellular activity of NH/GM, NH/LVF and their controls against S. aureus-infected 
HaCaT. Viable cell counts were calculated using three biological replicate count data (each derived from three 
technical replicate data). All data were Log10 transformed and are expressed as the mean value ± standard deviation. 
Statistical significance was determined using biological replicate data (n=3) with Mann-Whitney test by using SPSS 20 
Software. P values < 0.05 were considered significant. Asterisk denote statistically significant differences (*P<0.05). 
 
 
  
Figure 5. Flow cytometry analysis of HaCaT cells incubated with rhod-NHs. Cells were cultured in complete DMEM for 
48 h and then incubated from 0.5 to 24 h with 100 µg mL-1 rhod-NHs (A) or with 20-500 µg mL-1 of rhod-NHs for 4 h 
(B). Results were obtained in triplicate (n=3). All data are expressed as the mean value ± standard deviation.  
 
 
 
 
 
 
 
  
Figure 6. ApoTome micro-graphs (scale bars: 20 µm) of HaCaT cells incubated with 100 µg mL-1 rhod-NHs (A (merge), B 
(DAPI), C (rhod-NHs) or free rhod (D (merge), E (DAPI), F (rhod)). Cells were cultured in complete DMEM for 48 h and 
then incubated for 4 h with fluorescent nanoparticles.  
 
 
 
  
 
Figure 7. ApoTome micro-graphs (scale bar: 10 µm): co-localization with lysosomes. HaCaT cells were cultured in 
complete DMEM for 48 h and then incubated from 1 to 24 h with 100 µg mL-1 rhod-NHs. After specific time points 
slides were washed with PBS, added again to 1.5 mL of complete DMEM and finally treated with 1 mL of Lyso-Tracker 
Green’ (final conc. of 200 nM) for 3 min at 37°C. Images were immediately recorded on living cells. Pearson’s 
correlation coefficient was calculated using the AxioVision 4.8.2 software (Zeiss) and expressed as the mean value ± 
standard deviation.   Results were obtained from three independent experiments, each derived from eight images. 
Statistical significance was determined with One-way ANOVA analysis. Differences between groups were determined 
by a Turkey’s multiple comparison test. Asterisks denote statistically significant differences with the incubation time of 
1 h (*P<0.05; **P<0.01; ***P<0.005). 
 
 
  
 
 
 
 
 
 
Figure 8. Scheme of the intracellular fate of free GM (A), LVF (B) and their nano-formulations in S. aureus-infected 
keratinocytes. 
 
 
Table 1. Drug loading (DL, %) and loading efficiency (LE, %) of NH/GM and NH/LVF prepared at several HA-CH:GM or 
HA-CH:LVF wt. ratios (ranging from 1:1 to 1:0.25). Nano-systems highlighted (bold) were chosen for the biological and 
microbiological analyses. Experiments were performed in triplicate (n=3) and results are expressed as the mean value 
± standard deviation. 
 
Sample DL% LE% 
NH/GM (1:1) 40.0 ± 1.0 40.0 ± 1.0 
NH/GM (1:0.5) 35.1 ± 2.8 17.5 ± 1.4 
NH/GM (1:0.25) 30.7 ± 2.0 7.7 ± 0.5 
NH/LVF (1:1) 11.4 ± 3.1 11.4 ± 3.1 
NH/GM (1:0.5) 9.5 ± 2.0 4.74 ± 1.0 
NH/GM (1:0.25) 7.9 ± 0.8 2.0 ± 0.2 
 
